Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026)

Verano Holdings' (VRNO) quarterly Non-Current Deferred Tax Liability came in at $36.7 million in Q1 2026, down 49.73% year-on-year from $73.0 million in Q1 2025, and little changed on a QoQ basis from $36.6 million in Q4 2025.

Verano Holdings (VRNO) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $36.7 million in Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 49.73% year-over-year to $36.7 million in Q1 2026; TTM through Mar 2026 was $36.7 million, a 49.73% decrease from a year earlier, with the FY2025 full-year figure at $36.6 million, down 63.85% from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 stood at $36.7 million, roughly flat from $36.6 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for VRNO reached as high as $259.3 million in Q2 2022 and fell as low as $2.7 million in Q1 2022.
  • Historically, Non-Current Deferred Tax Liability has averaged $140.2 million across 5 years, with a median of $174.8 million in 2024.
  • Across the five-year window, Non-Current Deferred Tax Liability jumped 26219.88% in 2022 and sank 63.85% in 2025, its largest moves.
  • Year by year, Non-Current Deferred Tax Liability stood at $209.0 million in 2022, then decreased by 12.8% to $182.2 million in 2023, then tumbled by 44.38% to $101.4 million in 2024, then sank by 63.85% to $36.6 million in 2025, then grew by 0.11% to $36.7 million in 2026.
  • Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $36.7 million in Q1 2026, $36.6 million in Q4 2025, and $71.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Verano Holdings 2.02 Bn 1.94 Bn 98.98 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 36.69 Mn
Mar 31, 2026 36.69 Mn
Dec 31, 2025 36.64 Mn
Dec 31, 2025 36.64 Mn
Sep 30, 2025 71.02 Mn
Sep 30, 2025 71.02 Mn
Jun 30, 2025 72.37 Mn
Jun 30, 2025 72.37 Mn
Mar 31, 2025 72.98 Mn
Mar 31, 2025 72.98 Mn
Dec 31, 2024 101.36 Mn
Dec 31, 2024 101.36 Mn
Sep 30, 2024 168.16 Mn
Sep 30, 2024 168.16 Mn
Jun 30, 2024 174.79 Mn
Jun 30, 2024 174.79 Mn
Mar 31, 2024 180.25 Mn
Mar 31, 2024 180.25 Mn
Dec 31, 2023 182.22 Mn
Dec 31, 2023 182.22 Mn